ISCHEMIA IMPAIRS VASODILATION IN SKELETAL MUSCLE RESISTANCE
ARTERY

A Thesis
presented to
the Faculty of California Polytechnic State University,
San Luis Obispo

In Partial Fulfillment
of the Requirements for the Degree
Master of Science in Biomedical Engineering

by
Kyle Remington Struthers
June 2011

© 2011
Kyle Remington Struthers
ALL RIGHTS RESERVED
ii

COMMITTEE MEMBERSHIP

TITLE:

Ischemia Impairs Vasodilation in Skeletal Muscle
Resistance Artery

AUTHOR:

Kyle Remington Struthers

DATE SUBMITTED:

June 2011

COMMITTEE CHAIR:

Dr. Trevor Cardinal, Assistant Professor

COMMITTEE MEMBER:

Dr. Kristen O’Halloran Cardinal, Assistant Professor

COMMITTEE MEMBER:

Dr. Scott Hazelwood, Associate Professor

iii

ABSTRACT
Ischemia Impairs Vasodilation in Skeletal Muscle Resistance Artery
Kyle Remington Struthers

Functional vasodilation in arterioles is impaired with chronic ischemia. We
sought to examine the impact of chronic ischemia and age on skeletal muscle resistance
artery function. To examine the impact of chronic ischemia, the femoral artery was
resected from young (2-3mo) and adult (6-7mo) mice and the profunda femoris artery
diameter was measured at rest and following gracilis muscle contraction 14 days later
using intravital microscopy. Functional vasodilation was significantly impaired in
ischemic mice (14.4±4.6% vs. 137.8±14.3%, p<0.0001 n=8) and non-ischemic adult mice
(103.0±9.4% vs. 137.8±14.3%, p=0.05 n=10). In order to analyze the cellular
mechanisms of the impairment, a protocol was developed to apply pharmacological
agents to the experimental preparation while maintaining tissue homeostasis. Endothelial
and smooth muscle dependent vasodilation were impaired with ischemia, 39.6 ± 13.6%
vs. 80.5 ± 11.4% and 43.0 ± 11.7% vs. 85.1 ± 10.5%, respectively. From this data, it can
be supported that smooth muscle dysfunction is the reason for the observed impairment
in arterial vasodilation.

Keywords: Vascular Function, Age, Impaired Vasodilation, Endothelial Dysfunction,
Ischemia, Arteriogenesis, Mouse, SDF Imaging, Gracilis, Peripheral Artery Disease
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INTRODUCTION
CIRCULATORY FUNCTION
The circulatory system is composed of the heart, which pressurizes the blood, and
a complex network of blood vessels which deliver nutrients and remove wastes from
tissues through the continuous circulation of blood (Figure 1) [1, 2]. Blood flow begins
in the heart and is pumped through the body by muscular constriction of the left ventricle.
From the heart, blood enters elastic conduits called arteries (Figure 2). From there,
arteries stem smaller conduits called arterioles and further down the line these feed into
capillaries. The venous circulation, venuoles and veins, return blood back to the heart [1].

Figure 1: Circulatory System Anatomy. Diagram showing the heart, arteries, and veins
of the circulatory system.
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Figure 2: Vessel Architecture and Function. Diagram showing the direction of flow
from the heart through the various blood vessels, back to the heart. Adapted from [3].

Vessel function is determined by tissue structure (Figure 3). Arteries have a large
amount of elastic tissue which allows them to absorb the large pressure differentials that
the beating heart creates [1]. The arterioles are responsible for flow control to the distal
tissues, which is enabled by the large amount of smooth muscle in its medial layer [1].
Nutrient exchange is facilitated in capillaries due to their single layer of intimal
endothelial cells [1].

2

Figure 3: Blood Vessel Anatomy. Diagram shows the various tissue layers in an artery,
vein and capillary. Adapted from [1].

The volume of blood in the circulatory system is relatively constant, however the
distribution of this volume in different regions of the body is highly variable and can be
altered by factors such as the output of the left ventricle and the contractile state of the
resistance vessels of these regions [2]. With increased sympathetic activity, blood flow to
the body increases due to an increased heart rate [1]. It also causes rapid firing of
sympathetic fibers which innervate the vascular system, causing blood vessels to constrict
and increase peripheral resistance [1].
3

In the regions with increased metabolic demand, which causes an increase in
pCO2, a higher exchange rate is needed due to nutrient consumption and waste formation
rate [1]. For example, during exercise, muscles require more blood flow to match the
increase in energy expenditure. This flow control is accomplished by the arterioles,
located immediately upstream of the capillaries, which increase the lumen diameter by
relaxation of the surrounding smooth muscle [1]. In metabolically high areas of the body,
the density of these vessels is greater to allow for more nutrient and waste exchange [2].
The spontaneous, rhythmic contraction of blood vessels, specifically arterioles
and feed arteries, is involved with regulating blood flow throughout the body (Figure 4)
[2]. Vasoactivity serves either of two physiological purposes: regulation of systemic
blood pressure or redirecting blood flow to different regions of the body [4]. This
happens through vasoconstriction and vasodilation; which decreases and increases blood
perfusion to distal tissues respectively [4]. One example of the profound effect
vasoactivity can have on blood flow is the observation that aerobic exercise can increase
perfusion nearly 100 times when compared to rest [5]. When working properly, different
tissues can control the perfusion of their tissue through autoregulation. Autoregulation is
the ability of tissues to adjust blood flow with regards to the levels of tissue metabolism,
and vessel pressure [2, 4]. One of the main interests in this area of research is the future
ability to control vascular function, in regions of dysfunction, through the use of drugs.

4

Vasodilation. Vasodilation is an increase in luminal
Figure 4:: Vasoconstriction and Vasodilation
diameter and vasoconstriction is a decrease in luminal diameter. Adapted from [6].

Circulatory Dysfunction
Blood flow supply to tissues must match metabolic demand to maintain tissue
function, otherwise a medical pathology occurs. For example, if resistance vessel tone is
not maintained, increased capillary hydrostatic pressure will cause blood filtration and
edema1 can occur [2]. If the blood flow is reduced below the proper range,
range it causes a
decrease in blood supply to a distal tissue and it becomes ischemic ((Figure
Figure 5) [1].
Ischemia is insufficient tissue blood flow and results in hypoxia and poor nutrient
delivery to cells [7].. In healthy tissue, vasodilation appears immediately after the
beginning of hypoxia and can be maintained for several hours [7]. Unfortunately,
Unfortunately the
vasodilation process is impaired in patients with Peripheral Artery Disease (PAD), and
the treatment of this dysfunction is the motivation for this research [8].

1

Edema is a condition in which tissue becomes swollen and puffy due to increased fluid concentrations [1]
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Figure 5: Peripheral Artery Disease (PAD). Peripheral artery disease is a progression
of atherosclerosis in the distal limbs. It is characterized by a narrowing of the lumen of an
artery. Adapted from [9].

PERIPHERAL ARTERY DISEASE
Ischemic vascular disease is the leading cause of morbidity and mortality in the
developed world [10]. In the United States alone, PAD affects 8 million adults, a number
that will more than likely get larger as the population ages [11]. Many factors may lead to
6

this disease, including hypertension, smoking, diabetes mellitus and hypercholesteremia
[12]. At the cellular level, inflammation and endothelial dysfunction are contributing
factors to this disease [12-14], and there is general agreement that atherosclerosis begins
with a damaged or dysfunctioning endothelium [2, 13, 15]. Endothelial dysfunction
during atherogenesis is characterized by increased expression of adhesion molecules and
an increased synthesis of inflammatory and pro-thrombotic factors [13]. Adhesion
molecules enhance the attachment of monocytes, T lymphocytes, and platelets to the
endothelium [2]. Once macrophages extravasate into the artery wall, they begin
modifying the structure of the surrounding smooth muscle cells [2]. Later in the process,
cholesterol begins to build-up in the sub-endothelial space [14].
As this process progresses, the diameter of the lumen of the vessels becomes
smaller and smaller, known as stenosis. One of the symptoms of this disease is
intermittent claudication, or ischemic leg pain when the patient walks or climbs stairs [2].
With minimal walking, in patients with PAD, the resistance vessels lose the ability to
become maximally dilated. When the oxygen demand increases with more rapid walking
or climbing, blood flow cannot increase sufficiently to meet the muscle needs for oxygen,
and pain caused by muscle ischemia results [2]. It is also thought that the ischemia–
reperfusion injury associated with intermittent claudication could be among the causes
for increased inflammatory activity and endothelial dysfunction in PAD patients [16].
One percent to two percent of PAD patients over the age of 50 develop critical limb
ischemia (CLI) which begins with pain of the limb at rest and leads to tissue ulcers,
necrosis and eventually amputation [17]. The one year mortality rate of patients with CLI
is 20%, and at five years this rate increases to 50% [15]. Clearly, there is a need for
7

treatment of this disease and the goal of this research is to address the problem of
impaired vasodilation in these patients.

Treatment of PAD
The goal of contemporary treatments of PAD is to reverse conduit artery stenosis
and restore tissue blood flow through percutaneous angioplasty or by-pass surgery
(Figure 6) [18]. Endovascular angioplasty, the process of using a balloon to open up
occluded arteries in the peripheral vascular system, has been shown to increase flowmediated dilation [16]. Another avenue besides surgical treatments is drug therapy. In
addition to these surgical approaches, endogenous compensation of arterial stenosis
during PAD can occur through the development of collateral flow paths [18]. Therapeutic
stimulation of this process has received substantial attention in patients for which surgical
approaches are ineffective or contraindicated [18]. In order to properly stimulate this
process, the cellular mechanisms must be fully understood.

8

Figure 6: Angioplasty. Vascular angioplasty involves the insertion of a balloon catheter
into the stenosed area. The balloon is then inflated to increase the luminal diameter,
increasing perfusion of downstream tissue. Adapted From [20].
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There have been many advances in the understanding of the molecular and
cellular mechanisms responsible for collateral development [19]. Some of these
molecules include VEGF, FGF-2, FGF-1 and MCP-1, which have been shown to enhance
collaterogenesis [19]. Despite our improved understanding of arteriogenesis and
significant success of preclinical trials, therapeutic vascular growth has not been
successful in a clinical setting [18, 19]. It is unknown why arteriogenesis therapies have
not worked, but it could be due to the competing mechanisms of atherosclerosis and
arteriogenesis [19]. Regardless, it is necessary to study the process more. However,
collateral growth is a complex remodeling process, and it may be more straight-forward
to improve vasodilation in these patients.

MECHANISMS OF VASCULAR GROWTH
Following an occlusive event, the peripheral circulation remodels in response to
the altered flow and pressure through vasculogenesis, angiogenesis, and arteriogenesis
[21]. Vasculogenesis occurs primarily during embryonic development when angioblasts
differentiate to form primitive capillary plexuses [21], but has been observed in response
to hindlimb ischemia [22]. The peripheral circulation remodels in response to altered
flow and pressure through arteriogenesis in response to cellular hypoxia through
angiogenesis, these processes form collaterals and an expanded exchange network,
respectively [1, 2].
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Angiogenesis
Angiogenesis is the growth of new capillaries from existing capillaries. Although
angiogenesis can be induced by increased shear stress [23], in the context of ischemia,
angiogenesis is primarily induced by hypoxia (Figure 7) [18]. Hypoxia increases the
activity of hypoxia inducible factor-1 (HIF-1), a transcription factor that increases the
expression of hypoxia-sensitive genes, such as VEGF, which is the most well-studied
angiogenic factor in the context of both tumor growth and ischemic revascularization
[18]. Various growth factors, such as VEGF, promote the division of endothelial cells,
which organize into a hollow tube that sprouts out of the existing capillary. The resulting
sprouting capillary reconnects to its original capillary branch or a different one,
completing the angiogenic process [2]. Increasing capillary number will improve
diffusive transport in the ischemic tissue. However, arteriogenesis affects larger vessels,
which are more relevant to this work.

11

Angiogenesis. Diagram showing the growth of capillaries through
Figure 7:: Angiogenesis
angiogenesis. Not
Note the growth of capillaries from preexisting capillaries.
Arteriogenesis
Arteriogenesis refers to the transformation of pre
pre-existing
existing collateral artery
pathways into conduit arteries ((Figure 8) [24].. The process begins when a sudden arterial
arter
occlusion or a slowly progressing stenosis causes an increase in fluid shear forces on the
endothelium of the collateral flow path [21].. Normal shear values in arterial circulation
ranges between 10 and 70 dyn cm-2 [18].. When the range is breached, the elevated shear
activates
ivates the endothelial cell signaling pathways and results in increased transcription of
nitric oxide synthase (NOS), platelet
platelet-derived
derived growth factor (PDGF) and monocyte
chemoattractant protein-11 (MCP
(MCP-1) [21].. The activity of NOS is also increased
incre
and its
activity accounts for the vasodilation observed in response to increase
increased endothelial shear
[7]. The elevated shear also causes adhesion molecule presentation on the luminal surface
12

of the endothelium. Adhesion molecules, such as ICAM are necessary to “grab”
circulating monocytes, which adhere in response to MCP-1 [21]. Monocyte adherence
potentiates endothelial activation, which causes tumor necrosis factor-α (TNF-α) release,
further enhancing monocyte adhesion to the endothelium [21]. At the same time, platelets
adhere to the endothelium and produce interleukin-4 (IL-4), which amplifies the
expression of adhesion molecules [21].

Figure 8: Effects of Shear Stress on Arteriogenesis. The effects of a reperfusion study
on a rabbit hindlimb. (A) Reperfusion treatment (B) ligation treatment. Image was a post
mortem angiography. Adapted from [26].

Once they extravasate, monocytes produce many growth factors, such as
fibroblast growth factor-2 (FGF-2), which cause mitosis of the endothelial and smooth
muscle cells [21]. Mast cells, which are converted from basophils, secrete basic fibroblast
growth factor (bFGF) and vascular endothelial growth factor (VEGF) and may remain in
the tissue for up to 6 weeks [25]. Finally, matrix-metalloproteinases begin to digest the
extracellular matrix and provide the space for new cells and enable smooth muscle cells
13

to migrate towards the intima [25]. This generates an inflammatory response that attracts
T cells which causes smooth muscle cells to undergo apoptotis, creating space for the
increasing collateral vessel [21, 25]. Those smooth muscle cells that proliferate change
their phenotype and lose most of their contractile function [25] when they become
“synthetic”, or proliferative [21]. Once the vessel diameter has increased enough to return
shear stress back to the baseline levels, arteriogenesis will stop. This process increases
flow to the downstream tissue until the endothelial cells sense normal shear stress ranges.
There are several methods of increasing growth of collateral arteries. One of the
first substances found to increase arteriogenesis was MCP-1 [27]. Unfortunately this
compound also was shown to be pro-atherogenic, precluding its testing beyond
preclinical trials (Figure 9) [18, 19].
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Figure 9: Relation between Collaterogenesis and Atherogenesis. This diagram shows
pathways that are common to atherogenesis and collaterogenesis. Adapted from [19].

Monocytes recruitment can also be improved by granulocyte-monocyte colony
stimulating factors (GM-CSF) and granulocyte colony stimulator factor (G-CSF) [18],
15

which along with transforming growth factor beta (TGF-β), enhance arteriogenesis [24].
Unfortunately, both of these compounds promote tumor angiogenesis and atherosclerosis
[18].
VEGF expression is critical for the presence of collaterals and collateral growth,
likely through stimulation of endothelial proliferation. Unfortunately, the positive effect
of VEGF on vascularization in animal models [10, 28] has not been observed in large
clinical trials [29]. In addition to a lack of efficacy, VEGF therapies are associated with
edema, due to the ability of VEGF to increase endothelial permeability [19, 24].
To diminish these risks of side effects, many efforts have been made to deliver the
arteriogenic drugs locally [24], rather than intravascularly [18, 30]. Current research
predicts future methods to deliver these drugs through therapeutic devices such as stents.
These stents would elute a pro-arteriogenic compound into the affected artery over a
period of time, mitigating current delivery complications [18, 24]. Additionally, the risk
factors that cause PAD such as age, hypercholesterolemia, genetic susceptibility, diabetes
and smoking may also impair the efficacy of these therapeutic interventions [31]. Due to
the complexity of the arteriogenesis pathway, multiple therapeutic agents or cell-based
therapies may be needed to achieve efficacy [18, 31].
Cell based therapies refer to the process of isolating autologous cells and
delivering them to the patient [32]. Their usefulness, however, has been debated because
the process of growing collateral arteries is a local and self-sufficient process that is not
dependent on the circulating stem cells [25]. However, with dysfunction the
arteriogenesis pathway is broken, so delivering cells that can secrete many cytokines
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could be an effective modality to stimulate the process. Bone marrow derived progenitor
cells improve arteriogenesis, but their clinical efficacy remains inconclusive [18, 19].

MODELS OF ISCHEMIA
The main challenge of therapeutic arteriogenesis is there has been a history of
therapeutic efficacy in animal models followed by disappointing results in blinded and
randomized clinical trials [18, 31]. While there is no perfect model of PAD, many efforts
have been made to mimic the symptoms and pathologies of PAD to provide a better idea
of efficacy of treatments further down the line. [25]. Often these procedures involve
surgery, which takes a matter of minutes to hours; the time it takes for a human to
develop an atherosclerotic lesion is years to decades [33]. These inherent differences
require a better understanding of the animal models that are currently used. Fully
understanding these differences will help lead to more reasonable interpretations of the
results.
Experimental models of PAD can be divided into human and animal models.
Human models are limited from the perspective that invasive studies cannot be performed
and long-term studies are difficult. This is due to increased regulation enforced by the
Food and Drug Administration (FDA), specifically through the Office of Good Clinical
Practice (OGCP). Even with these difficulties human models are utilized. In one human
study, arterioles were isolated form amputated limbs for highly controlled studies of
vascular reactivity [34]. Conversely, non-invasive assessments, such as laser Doppler
perfusion imaging, can be performed routinely in patients with PAD [15].
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Comparatively, animal models can be used for long-term invasive studies.
Unfortunately, variability can be introduced through the numerous species and strains of
animals that can be used. Different types of surgical methods used to induce ischemia
also increase this variability. There are several experimental assessment endpoints that
must be addressed to properly analyze the efficacy of a therapy, such as vascular cell
proliferation, vascular number and size, and blood flow perfusion [35]. Many studies aim
to look at all of these factors; however there is no standard method to address these
experimental endpoints. This creates a need to understand the model being used in order
to develop experiments that properly evaluate the problem or efficacy of the solution.

Mouse and Rat Models
One of the most variable and simple of the animal models are rodents.
Advantages of these animals are their low cost, high reproductive rate, and general
similarity to human physiology. Historically, rats were the most common, but with the
emergence of mouse embryonic cell culture and genetic modification, mice have become
a more popular choice for experiments designed to establish causal relationships [36].
Through genetic manipulation, different co-morbidities can be induced, such as
hypercholesterolemia following the disruption of the genes involved in cholesterol
trafficking[37].
For ischemic research, two different surgical techniques are frequently used:
ligation and resection. During a ligation, the femoral artery is occluded with a suture,
preventing downstream flow [38]. The result of this occlusion is the enlargement of
superficial collateral arteries, which can be viewed in vivo one to three weeks after
18

femoral occlusion [38]. A resection surgery involves the removal of the femoral artery
and all of its branches from the hindlimb [39, 40]. Excision of the femoral artery results
in occlusion of the external iliac artery; blood flow to the ischemic limb is consequently
dependent on deep collateral vessels originating from the internal iliac artery [39, 40].
Often, a larger rodent model is used, such as a rat, which allows a greater range of
experimental options with regards to surgical methods [41]. There are still inherent
differences between the physiology of a human and a rodent. One example is the
difference between blood type proteins of a mouse and a human [42]. This can be seen on
the cellular level in embryonic stem cells [42]. This may explain why mice and rats have
not been predictive of a therapeutic effect on humans. To better match the diseased
human pathology and anatomy, a large animal model is considered.

Rabbit and Large Animal Models
Rabbit models are used for a variety of FDA and international biocompatibility
testing standards [43], chiefly in vascular research because their iliac artery diameter is
comparable to that of the human coronary artery and has similar thrombogenic properties
[43]. Other than the previously stated advantages, rabbits do not provide many more
advantages when compared to rats and larger animal models. However, they are used
frequently in ischemia research.
The most common ischemia models involve ligations and arteriovenous shunts,
which can be used to assess revascularizations in the rabbit hindlimb [28]. Arteriovenous
shunts involve the ligation of both femoral arteries and for the side-to-side anastomosis
operation of the distal stump of the left femoral artery with the accompanying vein [26].
19

This surgery re-routes vasculature and causes arterial vessels to drain into veins, which
have a lower hydrostatic pressure than downstream arterioles and hence causes an
increased pressure gradient and increased flow, resulting in an increased shear stress [26].
Similar to rodent studies, rabbits have predicted safety and positive responses to biologic
therapeutics [44].
When even larger models are needed, the most commonly used in ischemia
research are the porcine and canine model. Canines are often used because they are easy
to train and their circulation contains many collaterals for arteriogenesis research [35,
45]. The porcine model is advantageous because they can be given a high calorie diet and
gain similar pathologies to humans with PAD [43]. Animal species, surgical technique,
treatment and size must all be analyzed in order to improve their predictive capacity in
humans. Additionally, the differences in animal models can lead to differences in
responses when comparing across animal models. Thus inferring animal response to
humans needs to be done with caution and with careful consideration of the potential
differences. With a history of efficacy of therapies in animal models and inadequate
results seen in randomized patient trials, a different approach is needed if we want to
improve distal perfusion in those patients that are suffering from impairment [18, 31].
Therefore a better understanding of vascular function is needed.

MECHANISMS OF VASCULAR FUNCTION
Collateral growth is a complex process and more effective results could be
observed and complement or potentially replace therapeutic arteriogenesis by
determining how to improve vasodilation. As stated previously in the introduction, blood
20

flow is controlled by the increase and decrease of lumen diameter in the resistance
vasculature, arterioles, and feed arteries [1].

Vasoconstriction
Vasoconstriction involves the constriction of smooth muscle in a blood vessel to
decrease the luminal diameter and decrease blood velocity and distal perfusion [4].
Normally, vessel tone is maintained through constant activity from the sympathetic
nervous system [2]. Control of the vessel diameter can be divided into three separate
categories: local, neural, and hormonal mechanisms [4]. One of the most recognizable
ways of local vasoconstriction is in response to a cold stimulus which is a method of
preserving core body temperature [2]. Stimulation of this control pathway causes various
systemic effects, one of which is most relevant to this research, the increasing in
peripheral resistance through the use of neuroephinephrine [2]. Vessel pressure also has
an effect on vessel tone due to the myogenic response; vessels constrict in response to
high pressure [2]. There are several hormones that cause vasoconstriction, such as
Angiotensin II, which is a potent vasoconstrictor and a systemic way that blood pressure
is regulated [4]. Just as blood pressure can be increased through vasoconstriction, it can
be lowered through vasodilation.

Vasodilation
Vasodilation involves the relaxation of smooth muscle in a blood vessel to
increase the luminal diameter and increase blood velocity and distal perfusion [4]. Local
21

factors of vasodilation include substances that are released from the vessel endothelium
such as prostacyclin (PGI2) and nitric oxide (NO) [2]. Hormonal mechanisms of
vasodilation include atrial natriuretic peptide which causes vasodilation in the cardiac
vasculature [4]. Vasodilation in skeletal muscle is known to be regulated by muscle
metabolism, but to effectively increase flow, there must be coordination with vessels
outside of the metabolic field, such as feed arteries. This occurs through a mechanism
known as ascending vasodilation [46].
Ascending vasodilation is the process of the “spread” of a vasomotor response
along a blood vessel [5]. Research has demonstrated that this is due to electrical signals
that are capable of traveling for millimeters along the arteriolar endothelium [5, 47].
Ischemia may impair this process due to the resulting vascular dysfunction [48].

VASCULAR DYSFUNCTION
A healthy resistance vessel should dilate in response to ischemia. When this
mechanism is dysfunctional, the downstream tissue becomes transiently ischemic [2],
producing intermittent claudication. It is also thought that the injury associated with
intermittent claudication could be among the causes for increased inflammatory activity
and endothelial dysfunction in PAD patients [16]. One of the most common causes of
endothelial dysfunction and inflammation is diabetes mellitus [37, 49, 50].
Endothelial dysfunction and inflammation in diabetes is due to hyperglycemia and
it causes a decreased endothelial dependent relaxation due to increased thromboxane
receptors, enhancing vasoconstriction [49]. Similarly, endothelial dysfunction observed
in patients with PAD could be due to impaired endothelial vasodilator responses [11].
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In patients with chronic limb ischemia, feed arteries from ischemic skeletal
muscle showed exaggerated vasoconstrictor responses [51]. This was thought to be due to
an increase in both α-1 and α-2 adrenergic receptors in the ischemic tissue [51]. The goal
of this research is to better understand this mechanism to create efficacious treatments for
impaired α-adrenergic receptor responsiveness

Effects of Age
Age is one of the greatest risk factors for developing chronic ischemia [52]. Also,
there are greater numbers of older people in hospitals when compared to younger people
[53]. The effects of age on the human body are complex and include such as increased
blood pressure (hypertension) and impaired wound healing [4, 17]. Advanced age also
reduces muscle mass and increases vascular resistance [54]. Peripheral resistance is
directly tied to the material properties and the structural presence of blood vessels, which
changes with hypertension of blood vessels. As people get older, arteries lose their
elasticity and become stiffer with atherosclerosis and other pathologies [4]. Sympathetic
nerve activity also increases with age, causing vessels to be more constricted [54]. These
changes may explain the negative effect of age on arteriogenesis [31].
These vascular impairments are recapitulated in animal models, in which VEGF
expression was reduced in the ischemic limbs of aged mice and rabbits compared to
young animals [55]. Endothelial dysfunctional could represent a putative basis for agedependent impairments in angiogenesis [55]. Further, collateral numbers and endothelialdependent vasodilation were reduced in adult mice (6mo of age) [37]. Senescent mice,
aged 20 months exhibited reduced functional vasodilation, likely due to an increase in
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concentration of α-adenoreceptors in the microvasculature of an aged mouse [54]. From
this research, it is hypothesized that endothelial dysfunction is responsible for this
decrease in vasodilation in an aged, ischemic mouse.

THERAPEUTIC METHODS OF INCREASING VASCULAR FUNCTION
One of the only therapies currently known to increase vascular function is
exercise. Exercise therapy for patients with intermittent claudication increases pain-free
walking time, maximal walking time and overall physical capacity [41]. PAD patients
that are more physically active have increased flow-mediated dilation [11].
Unfortunately, many patients with PAD are restricted or prevented from participating in
these supervised exercise programs due to limited ability or lack of medical insurance
coverage [11]. Additionally, the molecular mechanism of this benefit is not understood,
consequently its therapeutic efficacy cannot be maximized. Additionally, to fully
understand how exercise benefits vasodilation, we must understand why vasodilation is
impaired in the first place. Therefore there is an obligation to discover alternative
methods of treatment such as drug and surgical intervention.
Some drug therapies to increase revascularization have been ineffective and have
many counterproductive side effects [19]. It is imperative for these new vessels to have
proper vascular function, unfortunately research has shown otherwise [5]. One possible
solution to this problem is the mechanism of eNOS. It is thought that eNOS causes an
increase in endothelial NO production which is a known vasodilator [2], and it has been
shown to increase skeletal muscle perfusion in a rat model [56].
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Despite our improved understanding of arteriogenesis and significant success of
preclinical trials, therapeutic vascular growth has not been successful in a clinical setting
[18, 19]. It is unknown why arteriogenesis therapies have not worked, but it could be due
to the competing mechanisms of atherosclerosis and arteriogenesis [19]. Regardless, it is
imperative that the mechanism is fully understood in order to properly address the
problem. More effective results could be observed and complement therapeutic
arteriogenesis by determining how to improve vasodilation in these patients. Vascular
function must improve in an ischemic environment, and resolving this problem is the
basis of this research.

OBJECTIVES AND HYPOTHESIS
The goal of this research is to better understand how ischemia affects vascular
function. This knowledge will help develop more effective therapies in the patient
population. To achieve this goal, the following Specific Aims were completed:

1. Specific Aim 1 –Test the hypothesis that age will decrease the functional
vasodilation during ischemia. The objective was to validate previous data on
3mo old mice, and advancing the data on 6mo old mice. It was also the
intention to validate results with a different group’s research performed on
mice at 3 and 6 months [37].
2. Specific Aim 2 - Establish a consistent superfused functional vasodilation
protocol using healthy mice. The goal of this aim was to create a reproducible
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protocol that allows studies to eventually use pharmacological agents during
functional vasodilation to assess specific aspects of dysfunction.
3. Establish an experimental protocol for assessing vascular reactivity using
pharmacological agents. The purpose of this aim was to explore the vascular
reactivity to endothelial dependent and smooth muscle dependent
vasodilators, as well as obtain a vascular range of motion with
vasoconstrictors.
4. Test the hypothesis that the ischemic profunda femoris artery will exhibit
impaired endothelial-dependent vasodilation. The purpose of this aim was to
explore the vascular reactivity to endothelial dependent and smooth muscle
dependent vasodilators in response to ischemia, as well as obtain a vascular
range of motion with vasoconstrictors.

Completing these aims will help further the experimental options of the lab while
discovering the potential mechanisms of dysfunction when ischemia is present.
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METHODS
HUSBANDRY
All procedures were reviewed and approved by the Institutional Animal Care and
Use Committee (IACUC) of the California Polytechnic State University in accordance
with the Guide for the Care and Use of Laboratory Animals. Male C57 mice aged 7-9
weeks were housed in the Cal Poly vivarium, with four mice to a micro-isolator cage.
The room was temperature controlled with a 12 hour to 12 hour light-dark cycle. Harlan
18% protein rodent chow and water were provided ad libitum. During cage changes,
isolation attire was worn to maintain aseptic conditions. Mice were monitored on a daily
basis and any notes were taken if irregularities in behavior were noticed.

FEMORAL ARTERY RESECTION PROTOCOL
Surgeries were performed using a stereomicroscope on male C57 mice under
sterile conditions using Isoflurane anesthesia (APPENDIX A). The hindlimb area was
first shaved and removed of hair. Nolvasan was used to disinfect the surgical field and
reduce the likelihood of infection. The mice were kept at a temperature of ~35 °C using a
rectal-thermistor controlled heating pad. A sterile drape was placed over the mouse with
an opening over the surgical area (Figure 10). Figure 11 shows the approximate area of
femoral artery and vein resected from the hindlimb. The first incision was made with a
straight cut over the medial thigh of the mouse. The cut was extended proximally until
the abdominal wall was visible. It was also extended distally to midway between the knee
and ankle. Sterile saline solution was used to irrigate the incision and prevent tissue
27

desiccation. Connective tissue was blunt dissected over the femoral neurovascular
bundle. Then, the epigastric fat pad and epigastric artery-vein pair were dissected using
blunt dissection and heat cauterization.

Figure 10: Surgical Setup. Picture showing the surgical suite. The mouse is shown
underneath the sterile drape. All surgical instruments and objects that touched the mouse
during surgery were kept sterile to prevent infection.
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Figure 11: Resected Region. (A) Hindlimb before resection. (B) Hindlimb with resected
area denoted by a black line. The distal hindlimb area is not fully visible.

Once the fat pad was removed, the femoral artery and vein pair was separated
from the nerve using gentle blunt dissection. The femoral artery and vein pair was then
ligated proximal to the profunda femoris with a 6-0 silk suture. The profunda femoris was
then cauterized as close to the femoral artery and vein pair as possible to minimize
hemorrhage following femoral artery-vein resection. The femoral artery-vein pair was
then ligated halfway between the knee and ankle. Veins branching off of the femoral
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artery-vein pair were cauterized to leave some native circulation intact. Great care was
taken by the surgeon to leave as many branches as possible. A cotton swab was used to
apply counter-pressure on the tissue while the femoral artery vein pair was carefully
pulled and separated from the underlying tissue and cut just distal to the proximal
ligation. Finally, the skin incision was closed using 7.0 polypropylene suture, Figure 12.
.

Figure 12: Suture Timeline. (A) Hindlimb before incision is made (B) Hindlimb after
resection surgery and suturing protocol (C) Hindlimb 14 days after surgery.

An incision, equivalent in length and placement, was made on the contralateral
limb. Sterile saline was used to irrigate the incision and prevent tissue desiccation.
Connective tissue over the femoral neurovascular bundle was blunt dissected similar to
the previous limb. This was done to create a sham limb, designed to control for any
effects of general surgical trauma. Finally, the skin incision was closed using 7.0
polypropylene suture. The mouse was then given a subcutaneous injection of
buprenorphrine (0.07 mg/kg) and placed in a warm recovery bin until ambulatory, then
was returned to the vivarium.
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INTRAVITAL MICROSCOPY WITH FUNCTIONAL VASODILATION PROTOCOL
SDF Imaging was used to evaluate profunda femoris artery diameter (APPENDIX
B). Experimental preparation/dissections were performed using a stereomicroscope. The
hindlimb area was first shaved and removed of hair and mice were maintained at ~35 °C
using a rectal-thermistor controlled heating pad. The initial incision was made with a
straight cut over the medial hindlimb of the mouse. The cut was extended proximally
until the abdominal wall was visible. Phosphate Buffered Saline (PBS) solution was used
to keep the incision irrigated and prevent tissue desiccation. Connective tissue was
carefully dissected away from the leg, as to not harm the underlying muscle. The
epigastric fat pad was then blunt dissected away from the abdominal wall, and cautery
was used to bisect the fat pad into two parts. This was done to allow placement of the
MicroScan over the profunda femoris artery.
Once the dissection was complete, the MicroScan was then placed over the
profunda femoris artery and positioned such that the anterior gracilis muscle was visible
at the bottom of the field of view. Two electrodes were then placed on the mouse
hindlimb: the ground electrode on the skin of the mouse and stimulating electrode above
the gracilis muscles (Figure 13). It was important to not puncture the muscle because this
caused unwanted hemorrhage. To test proper placement, the gracilis muscle was
stimulated with 1mA square waves 100µs in duration at 1 Hz until proper electrode
placement was confirmed. If the hindlimb twitched and was visible on the video image,
proper electrode placement was confirmed. At this point a KimWipe was used to remove
the remaining PBS solution from the hindlimb. Mineral oil was then placed on the
hindlimb using a pipette and covered with plastic wrap.
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Figure 13: Electrode Placement. Areas of interest are labeled. Note the placement of
the electrodes: on the gracilis muscle and on the skin. A retractor was used to fully show
the entire hindlimb area.

The mineral oil prevents the tissue from desiccating and creates an effective
barrier to prevent oxygen diffusion [57]. High pO2 may cause vasoconstriction and alter
basal tone as well as demand for oxygen. Therefore, to keep a controlled system, an
environment free from oxygen diffusion is very important.
The experimental preparation was allowed to recover for 30 minutes. Following
this recovery period, a 10 second video baseline measurement was taken. The gracilis
muscle was then stimulated with 1mA square waves 200µs in duration at 8 Hz for 90
second. 10 second videos were taken before stimulation, after stimulation, and every two
minutes afterwards until the resting diameter was reached, ±5µm. The gracilis muscle
was then stimulated with 1mA square waves 500µs in duration at 8 Hz for 90 seconds.
Again, 10 second videos were taken before stimulation, after stimulation, and every two
minutes afterwards until the baseline diameter was measured. After both stimulation
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protocols were complete, the hindlimb was covered with plastic wrap and the process was
repeated on the contralateral limb; the order of measurement was randomized between
the two limbs. This was done to prevent experimental error that was found when limb
order was not randomized [58]. After the protocol was completed on both limbs, the
mouse was euthanized by cervical dislocation. Sacrificed mice were stored in a -20°C
freezer and disposed in a biohazard waste container.

INTRAVITAL MICROSCOPY WITH SUPERFUSION PROTOCOL
In order to test the effects of pharmacological agents on the current model, a
method to apply them to the preparation without the use of mineral oil was needed.
Therefore a superfusion protocol was proposed (APPENDIX C). The superfusion
solution was a physiological salt solution (PSS) composed of the following compounds
(in mM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCaL2 2, and NaHCO3 18. Prior to each
experiment, the PSS was warmed in a water bath at 45°C and deoxygenated/pH-balanced
by bubbling with a 95%:5% N2:CO2 mixture for approximately 15 minutes. After the
solution was prepared, a portion of the liquid was poured into the superfusion circuit
(Figure 14).
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Figure 14: Superfusion Circuit. Diagrams of the circuit used to apply superfusion
solution on the hindlimb of the mouse. (A) Basic block diagram of the circuit (B) Image
of the actual circuit used in experiments.

SDF Imaging was again used to evaluate the diameter of the profunda femoris
artery, and the animal was prepared as described above. Once the dissection was
complete, the MicroScan was then placed over the profunda femoris artery and
positioned with the gracilis muscle at the bottom of the field-of-view. Superfusion
solution was adjusted to flow at ~2mL·min-1 and a thermistor was used to ensure that a
temperature of 35°C was maintained.
The limb was then allowed to recover for 30 minutes from the dissection.
Following this recovery period, a 10 second video baseline measurement was taken
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before the addition of pharmacological agents in the following order: neuroepinephrine
(10-4M), acetylcholine (10-4M), and sodium nitroprusside (SNP) (10-4M). Agents were
allowed to flow over the experimental preparation for 5 minutes; 10 second videos were
taken within the last minute. After the protocol was complete, the hindlimb was covered
with plastic wrap and the process was repeated on the contralateral limb. The order of
experimentation was alternated between the right and left hindlimbs for each mouse [58].
After the protocol was completed on both limbs, the mouse was euthanized by cervical
dislocation. Sacrificed mice were stored in a -20°C freezer and disposed of in a biohazard
waste container.

DRUG MECHANSIMS OF ACTION
Norepinephrine
Norepinephrine is one of the most important regulators of vasoconstriction in
skeletal muscle resistance vessels [1]. Norepinephrine is a catecholamine, which is a class
of amines that act as chemical transmitters [1], other examples include epinephrine and
dopamine [1]. In a stressful situation, neuroepinephrine is synthesized from tyrosine and
is secreted from sympathetic neurons that synapse on the smooth muscle [1]. Smooth
muscle cells then have different receptors that receive the neurotransmitter. Specifically
α1-adenoreceptors and α2-adenoreceptor and β-adenoreceptors [2], arterial
vasoconstriction is predominantly mediated by α1-adenoreceptors with a small
contribution from α2-adenoreceptors [34]. Previous studies have shown an increase in
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certain receptors due to ischemia, thus the motivation for using this drug in the research
[34]. Figure 15 shows the cellular mechanism of this endogenous neurotransmitter.

Figure 15: Neuroepinephrine Pathway. Concept map showing the cellular mechanism
of neuroepinephrine. It binds to specific receptors and results in smooth muscle
contraction, or in the case of blood vessels, vasoconstriction.
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Acetylcholine
Acetylcholine is a neurotransmitter that is released by nerve endings, specifically
the cholinergic fibers (Figure 16) [1]. Acetylcholine receptors are found on the
endothelial cell and when activated result in vasodilation [59, 60]. This compound is
typically used in order to assess endothelial dysfunction in vasodilation due to its ability
to produce a robust dilation that is endothelial dependent, which was the main motivation
in using this drug in the protocol [55]. However, there has been some debate regarding
this due to a group that showed that vasodilatory chemicals may act differently than the
natural pathway [61].
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Figure 16: Acetylcholine Pathway. Concept map showing the cellular mechanism of
acetylcholine. The process begins with acetylcholine binding to a cholinergic receptor
and results in vessel vasodilation. This is an endothelial dependent vasodilator.
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Sodium Nitroprusside
This mechanism is very similar to acetylcholine; only it completely skips the
endothelial process and goes directly to giving rise to stimulating sGC (Figure 17). NO
donors are typically used to assess smooth muscle functionality due to its mechanism,
which was the main motivation for using this drug in the study [55]. Nitrates are also
used as treatments for angina and cardiac ischemia in order to achieve greater blood flow
in the heart [62].

Figure 17: Sodium Nitroprusside Pathway. Concept map showing the cellular
mechanism of sodium nitroprusside. It begins with the donation of nitric oxide to the
smooth muscle cell, which results in vasodilation of the vessel. This is a smooth muscle
dependent vasodilator.
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SUPERFUSION PLUS FUNCTIONAL VASODILATION PROTOCOL
Superfusion intravital microscopy was performed as described above, with the
following modification (APPENDIX D). Once the MicroScan was placed over the
profunda femoris artery, a ground electrode and placed on the skin and a stimulating
electrode was placed above the gracilis muscles. Proper placement was confirmed with
test contractions and the superfusion solution was adjusted to ~2mL·min-1.
After the 30-minute recovery period, the gracilis muscle was stimulated with 1mA
square waves for 200µs or 500µs in duration at 8 Hz for 90 seconds. Ten-second videos
were taken before stimulation, after stimulation, and every two minutes afterwards until
baseline diameter was measured. After both stimulation protocols were complete, the
hindlimb was covered with plastic wrap and the process was repeated on the contralateral
limb. The order of experimentation was alternated between the right and left hindlimbs
for each mouse [58]. After the protocol was completed on both limbs, the mouse was
euthanized by cervical dislocation. Sacrificed mice were stored in a -20°C freezer and
disposed of in a biohazard waste container.

IMAGING AND STATISTICAL ANALYSIS
Automated Vascular Analysis (AVA) was used to measure diameters from
stabilized videos (APPENDIX E). Data was analyzed using the statistics package in
Microsoft Excel. Paired t-tests were used for data sets that showed a linear association
which was indicative of dependence between the two sets of data. This was true for all
data sets in the first Aim except for when comparing between adult and young mice, in
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which a one-way ANOVA was used. In Aims three and four, groups were compared by
using a one-way ANOVA. Summary data are represented as mean values ± standard
error.
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RESULTS
EFFECTS OF AGE & ISCHEMIA ON FUNCTIONAL VASODILATION
For Specific Aim 1 (Page 26), the hypothesis that age and ischemia reduce
functional vasodilation in the profunda femoris feed artery was tested. It was
hypothesized that the effects of these treatments would be additive, which was tested by
comparing age and ischemia individually against a control. Arteries were measured as
stated in the methods section (Figure 18).
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Figure 18:: Example of Profunda Femoris Measurements. Microscan images taken of
the profunda femoris artery (lighter color) on the hindlimb of the mouse. Taken at
different time points (A) Sham artery before stimulation. (B) Sham artery after 200 µs
stimulation, note increase in diameter. (C) Sham artery after 500 µs stimulation, note
smaller
ller increase in diameter. (D) Experimental artery before stimulation. (E)
Experimental artery after 200 µs stimulation, note increase in diameter. (F) Experimental
artery after 500 µs stimulation, note smaller increase in diameter
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Impact of Ischemia
In young mice (2-3mo), the resting ischemic artery was significantly larger than
the control artery, 103.1 ± 10.3 µm vs. 54.1 ± 3.6 µm, p= 0.0006 (n=8), (Figure 19).
However, arterial diameter was not different between ischemic and control arteries
following functional vasodilation (Table 1). Therefore, percent change in diameter
compared to resting state was examined as the more accurate indicator of vascular
reactivity (Figure 20). When the gracilis muscles were stimulated with 200 µs duration
square waves, control arteries dilated significantly more than ischemic arteries, 104.1 ±
13.0% vs. 15.2 ± 5.0%, p<0.001, (n=8) (Figure 20). When the gracilis muscles were
stimulated with 500 µs duration square waves, control arteries dilated significantly more
than ischemic arteries, 137.8 ± 14.3% vs. 14.4 ± 4.6%, p<0.0001 (n=8).

Profunda Femoris Diameter (µm)

Young Ischemic vs. Young Sham
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Figure 19: Young Ischemic vs. Young Sham. A bar graph of the profunda femoris
artery diameter during rest, after a 200 µs stimulation and 500µs stimulation *p=0.004
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Table 1: Ischemia Data Table (Young Mice). Average values taken from functional
vasodilation protocol with young mice (2-3mo), p value < 0.5 is significant

Young Sham

Young
Ischemic

p value

54.1 ± 3.6 µm

103.1 ± 10.3 µm

0.0006

Moderate Contraction
(200µs duration)

108.3 ± 6.0 µm

116.8 ± 10.0 µm

0.48

Intense Contraction
(500µs duration)

125.8 ± 4.6 µm

117.0 ± 11.7 µm

0.50

Rest vs. Post 200µs
Stimulation % Change

104.1 ± 13.0 %

15.2 ± 5.0 %

0.0002

Rest vs. Post 500µs
Stimulation % Change

137.8 ± 14.3 %

14.4 ± 4.6 %

0.00003

Rest

Percent Change in Profunda Femoris
Diameter

Young Ischemic vs. Young Sham % Change
160
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Figure 20: Young Ischemic vs. Young Sham % Change. A bar graph of the profunda
femoris artery diameter percent change comparing post 200 µs stimulation to rest and
post 500 µs stimulation to rest *p<0.001 ×p<0.0001
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Impact of Age
To test a corollary of the main hypothesis for this aim, the impact of age alone on
function vasodilation was examined. There was a trend towards a larger resting diameter
in the adult mice, 62.4 ± 4.9 µm vs. 54.1 ± 3.6 µm, this difference did not achieve
statistical significance, p=0.21 (n=10/8) (Figure 21). However, arterial diameter was not
different between young and adult arteries following functional vasodilation (Table 2).
Therefore, percent change in diameter compared to the resting state was examined as the
more accurate indicator of vascular reactivity (Figure 22). When the gracilis muscles
were stimulated with 200 µs duration square waves, there was a trend towards larger
young artery dilation, 104.1 ± 13.0% vs. 79.8 ± 11.9%, this difference did not achieve
statistical significance, p=0.19 (n=8/10) (Figure 22). When the gracilis muscles were
stimulated with 500 µs duration square waves, young arteries dilated significantly more
than adult arteries, 137.8 ± 14.3% vs. 103.0 ± 9.4 %, p=0.05 (n=8/10).

Profunda Femoris Diameter (um)

Adult Sham vs. Young Sham
140
120
100
80
Adult

60

Young

40
20
0
Rest

200us

500us

Figure 21: Adult Sham vs. Young Sham. A bar graph of the profunda femoris artery
diameter. Note the increase in adult resting diameter compared to the young resting
diameter.
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Table 2: Age Data Table (Sham Limb). Average values taken from functional
vasodilation protocol with adult mice (6-7mo) and young mice (2-3mo) from the sham
limb, p value < 0.5 is significant

Young Sham

Adult Sham

p value

54.1 ± 3.6 µm

62.4 ± 4.9 µm

0.21

Moderate Contraction
(200µs duration)

108.3 ± 6.0 µm

108.0 ± 5.5 µm

0.98

Intense Contraction
(500µs duration)

125.8 ± 4.6 µm

123.8 ± 7.8 µm

0.84

Rest vs. Post 200µs
Stimulation % Change

104.1 ± 13.0 %

79.8 ± 11.9 %

0.19

Rest vs. Post 500µs
Stimulation % Change

137.8 ± 14.3 %

103.0 ± 9.4 %

0.05

Rest

Percent Increase in Profunda
Femoris Diameter

Adult Sham vs. Young Sham % Change
160

*

140
120
100
80

Adult

60

Young

40
20
0
200us

500us

Figure 22: Adult Sham vs. Young Sham % Change. A bar graph of the profunda
femoris artery diameter percent change comparing post 200 µs stimulation to rest and
post 500 µs stimulation to rest. Note the increase in adult resting diameter compared to
the young resting diameter. *p=0.05
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Impact of Age and Ischemia
A similar pattern of profunda femoris diameters was observed in adult mice (67mo). The resting ischemic artery was significantly larger than the control artery, 102.9 ±
10.3 µm vs. 62.4 ± 4.9 µm, p=0.004 (n=10), (Figure 23). However, arterial diameter was
not different between ischemic and control arteries following functional vasodilation
(Table 3). Therefore, percent change in diameter compared to the resting state was
examined as the more accurate indicator of vascular reactivity (Figure 24). When the
gracilis muscles were stimulated with 200 µs duration square waves, control arteries
dilated significantly more than ischemic arteries, 79.8 ± 11.9% vs. 7.6 ± 3.4%, p
<0.00001 (n=10) (Figure 24). When the gracilis muscles were stimulated with 500 µs
duration square waves, control arteries dilated significantly more than ischemic arteries,
103.0 ± 9.4% vs. 16.8 ± 5.9%, p=0.000002 (n=10). Age did not affect the resting
diameter or functional vasodilation of the ischemic artery (Table 4, Figure 25, and
Figure 26).
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Figure 23: Adult Ischemic vs. Adult Sham. A bar graph of the profunda femoris artery
diameter during rest, after a 200 µs stimulation and 500µs stimulation *p=0.0006

Table 3: Age and Ischemia Data Table (Adult Mice). Average values taken from
functional vasodilation protocol with adult mice (6-7mo). Chart shows average vessel
diameters and percent change from rest at rest, moderate contraction and intense
contraction. p value < 0.5 is significant.

Adult Sham

Adult
Ischemic

p value

62.4 ± 4.9 µm

102.9 ± 10.3 µm

0.004

Moderate Contraction
(200µs duration)

108.0 ± 5.5 µm

111.8 ± 12.2 µm

0.78

Intense Contraction
(500µs duration)

123.8 ± 7.8 µm

119.2 ± 12.2 µm

0.75

Rest vs. Post 200µs
Stimulation % Change

79.8 ± 11.9 %

7.6 ± 3.4 %

0.00003

Rest vs. Post 500µs
Stimulation % Change

103.0 ± 9.4 %

16.8 ± 5.9 %

0.000002

Rest
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Figure 24: Adult Ischemic vs. Adult Sham % Change. A bar graph of the profunda
femoris artery diameter percent change in adult mice comparing post 200 µs stimulation
to rest and post 500 µs stimulation to rest *p<0.0001 ×p<0.00001

Table 4: Age and Ischemia Data Table (Young and Adult Mice). Average values
taken from functional vasodilation protocol with young mice (2-3mo) and adult mice (67mo). Chart shows average vessel diameters and percent change from rest at rest,
moderate contraction and intense contraction. p value < 0.5 is significant

Young
Ischemic

Adult
Ischemic

p value

103.1 ± 10.3 µm

102.9 ± 10.3 µm

0.99

Moderate Contraction
(200µs duration)

116.8 ± 10.0 µm

111.8 ± 12.2 µm

0.77

Intense Contraction
(500µs duration)

117.0 ± 11.7 µm

119.2 ± 12.2 µm

0.90

Rest vs. Post 200µs
Stimulation % Change

15.2 ± 5.0 %

7.6 ± 3.4 %

0.21

Rest vs. Post 500µs
Stimulation % Change

14.4 ± 4.6 %

16.8 ± 5.9 %

0.76

Rest
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Figure 25: Adult Ischemic vs. Young Ischemic. A bar graph of the profunda femoris
artery diameter averages in adult and young ischemic mice. No clear difference was seen.
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Figure 26: Adult Ischemic vs. Young Ischemic % Change. A bar graph of the
profunda femoris artery diameter percent change in young and adult ischemic mice
comparing post 200 µs stimulation to rest and post 500 µs stimulation to rest.
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SUPERFUSED FUNCTIONAL VASODILATION PROTOCOL
For Specific Aim 2 (Page 26), a protocol was developed for a superfused
functional vasodilation. This was completed to eventually test the effects of
pharmacological agents on the current model during a functional vasodilation protocol.
This protocol solves the problem of not being able to add drugs to the preparation
through mineral oil. By adding the drugs to a superfusion solution, pharmacological
agents can be easily added to the preparation. The goal was to create a consistent protocol
with minimal dilation caused by the superfusion solution.
No significant difference in diameter was noticed between the right and left limb
(Figure 27, Table 5). However, arterial diameter increased following the addition of the
superfusion solution 89.7 ± 11.3 µm vs. 50.4 ± 6.8 µm, p=0.0007 (n=10) (Table 6).
Looking at percent change in diameter, vascular reactivity to the superfusion solution was
more accurately examined (Figure 28). Following the addition of the superfusion
solution, arterial diameter increased 84.3 ± 13.0% for the left limb and 65.6 ± 17.2% for
the right limb.
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Figure 27: Superfused Functional Vasodilation: Right vs. Left Comparison.
Profunda femoris artery diameter measurements at rest, 30 minutes after superfusion
solution was applied, and after a 500 µs stimulation. No significant differences were
observed between right and left limbs.

Table 5: Superfused Functional Vasodilation Data Table. Average values taken from
superfused functional vasodilation protocol. Chart shows average vessel diameters and
percent change from rest at rest, moderate contraction and intense contraction.

Rest
Post Superfusion
Post Stimulation
Rest vs. Post
Superfusion % Change
Rest vs. Post
Stimulation % Change

Left Limb

Right Limb

50.4 ± 6.8 µm

56.6 ± 4.7 µm

89.7 ± 11.3 µm

89.9 ± 9.0 µm

101.5 ± 9.6 µm

112.6 ± 5.7 µm

84.3 ± 13.0 %

65.6 ± 17.2 %

116.0 ± 16.6 %

108.0 ± 14.0 %
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Table 6: Superfused Functional Vasodilation Data Analysis Table. Statistical analysis
of data in Table 5 n=10

Rest vs. Post
Superfusion
Post Superfusion vs.
Post Stimulation
Rest vs. Post
Stimulation

Left Limb
p values

Right Limb
p values

0.0007

0.003

0.04

0.004

0.00001

0.00000009

0.07

0.004

% Change

Percent change in profunda
femoris diamter
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Figure 28: Superfused Functional Vasodilation: Right vs. Left % Change
Comparison. Profunda femoris artery diameter percent change measurements. No
significant differences were observed between right and left limbs.
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SUPERFUSED VASOACTIVE AGENTS PROTOCOL
For Specific Aim 3 (Page 26), a protocol was developed for superfusing
vasoactive agents. This was completed to test the effects of pharmacological agents on
the current model by creating a method to apply them to the preparation without the use
of mineral oil. Previous work completed by this lab (Thomas Kessler) resulted in a
protocol for the use of two different drugs, Ach and SNP. The goal of this protocol was to
assess the potency of NE and examine the feasibility of using three different drugs in one
superfusion experiment. First, a dose response curve to NE was generated (Figure 29).
No significant difference between limbs was observed (Table 7).

Dose Response to NE
Profunda Femoris Diameter (um)
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0

Figure 29: Dose Response Curve to Neuroepinephrine. A plot of the diameters of the
profunda femoris artery with increasing doses of NE (in M). Note that the final dose is
KCl, a potent vasoconstrictor. No significant difference was found between limbs.
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Table 7: NE Dose Response Curve. Average values taken from superfusion protocol, p
value < 0.5 is significant

Rest

Left Limb

Right Limb

p value

110 ± 6 µm

105 ± 20 µm

0.78

107 ± 4 µm

106± 21 µm

0.98

105 ± 2 µm

106 ± 23 µm

0.96

108 ± 3 µm

105 ± 18 µm

0.87

106 ± 2 µm

102 ± 16 µm

0.82

41 ± 15 µm

66 ± 29 µm

0.32

42 ± 9 µm

47 ± 12 µm

0.34

-8

10 M NE
10-7 M NE
10-6 M NE
10-5 M NE
10-4 M NE
10-4 M KCl

No significant was noticed between limbs for the protocol setup (Figure 30,
Figure 31). Due to the large difference in diameter between ACh/SNP and NE, dynamic
range was calculated. No significant difference between limbs was noticed (Figure 32).
Because no significant differences were found between all groups, the protocol was
completed with sham and experimental groups.
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Figure 30: Superfusion: Right vs. Left. A bar graph of the profunda femoris artery
diameter and its response to three vasoactive agents: NE, Ach, and SNP. No significant
difference was found between limbs.

Superfusion: Right vs. Left % Change
Percent Change in Profunda Femoris
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Figure 31: Superfusion: Right vs. Left % Change. A bar graph of the profunda femoris
artery diameter percent change compared to resting diameter and its response to three
vasoactive agents: NE, Ach, and SNP. No significant difference was found between
limbs.
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Figure 32: Superfusion Dynamic Range. Dynamic ranges of the right and left limb.
The maximum was determined from the value of the SNP diameter and the minimum
from the NE diameter. No significant difference was found between limbs.

EFFECTS OF ISCHEMIA ON ENDOTHELIAL AND SMOOTH MUSCLE
DEPENDENT REACTIVITY
For Specific Aim 4 (Page 26), the hypothesis that ischemia reduces vascular
reactivity in the profunda femoris feed artery was tested. It was hypothesized that the
cause of this difference would be endothelial dysfunction.
There was no trend or significant difference noticed between the ischemic and
sham limbs for both the resting and NE diameters (Figure 33). There was a trend towards
a larger diameter in the sham artery when superfused with ACh, 133.8 ± 7.5 µm vs. 109.6
± 12.3 µm, this difference did not achieve statistical significance, p=0.12 (n=8). A similar
trend was seen with SNP, 137.5 ± 7.6 µm vs. 113.3 ± 12.7 µm, this difference did not
achieve statistical significance, p=0.12 (n=8). Due to the lack of significance, percent
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change in diameter compared to the resting state was examined as the more accurate
indicator of vascular reactivity (Figure 34). Again, when superfused with NE, no
significance was noticed between groups. When the hindlimb was superfused with ACh,
control arteries dilated significantly more than ischemic arteries, 80.5 ± 11.4% vs. 39.6 ±
13.6%, p=0.04, (n=8). When the hindlimb was superfused with SNP, control arteries
dilated significantly more than ischemic arteries, 85.1 ± 10.5% vs. 43.0 ± 11.7%, p=0.02,
(n=8). When dynamic range was calculated, the control arteries had a significantly larger
range, 112.4 ± 6.9 µm vs. 87.5 ± 9.4 µm, p=0.05, (n=8) (Figure 19).

Ischemic vs. Sham Superfusion Response
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Figure 33: Ischemic vs. Sham Superfusion Response. A bar graph of the profunda
femoris artery diameter and its response to three vasoactive agents: NE, Ach, and SNP.
No significant difference was found between limbs; however a trend was noticed for ACh
and SNP between groups.
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Figure 34: Ischemic vs. Sham % Change. A bar graph of the profunda femoris artery
diameter percent change compared to resting diameter and its response to three
vasoactive agents: NE, Ach, and SNP. A significant difference was observed between
ischemic and sham groups for the ACh percent change and SNP percent change *p<0.05

Dynamic Range
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Figure 35: Dynamic Range. Dynamic ranges of the ischemic and sham limb. The
maximum was determined from the value of the SNP diameter and the minimum from
the NE diameter. A significant difference was observed between ischemic and sham
groups *p=0.05.
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DISCUSSION
RESTATEMENT OF EXPERIMENTAL OBJECTIVES
To help guide the discussion of experimental results, the primary objectives of the thesis
are listed below:
1. Test the hypothesis that age will decrease the functional vasodilation during
ischemia.
2.

Establish a consistent superfused functional vasodilation protocol using healthy
mice.

3. Establish an experimental protocol for assessing vascular reactivity using
pharmacological agents.
4. Test the hypothesis that the ischemic profunda femoris artery will exhibit
impaired endothelial-dependent vasodilation.

AIM 1: IMPACT OF AGE ON FUNCTIONAL VASODILATION
Age is one of the greatest risk factors for developing chronic ischemia [52].
Systemic pathologies such as hypertension and impaired wound healing are also present
with advanced age [4, 17, 54]. One of the most pertinent effects of age, with regards to
this research, is its negative effect on revascularization, which have been recapitulated in
animal models [37, 54]. Acetylcholine-dependent dilation in vitro can be impaired as
early as 6 months of age [37], while in vivo functional vasodilation is known to be
decreased in mice of advanced age, 20 months [54]. Given the impact of age on
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vasodilation we hypothesized that age plus ischemia would have an additive effect on
reducing functional vasodilation.

Aim 1: Impact of Age on Functional Vasodilation
Age reduced the functional vasodilation response observed in the sham limb. In
young mice, the profunda femoris dilated 140% in response to 500 µs pulses vs. 100% in
adult mice. Furthermore, the young profunda femoris artery showed a non-significant
trend of a lower resting diameter 54 µm, compared to 62 µm in the adult animal. This
was similar to values from previous research, in which adult C57 mice exhibited less
resting tone than young C57 mice [37]. It was observed that the average weight of the
young mice was ~20g and that of the older mice was ~30g. There was also a considerably
higher amount of visible adipose tissue around the artery in the adult mice compared to
the young mice. Adipose tissue has been shown to increase vessel relaxation due to
adipocyte-derived relaxing factor (ADRF) [63], opens K+ channels in vascular smooth
muscle cells [64]. Therefore, an increase in adiposity may explain the lower resting tone
observed in the adult mice.

Aim 1: Impact of Ischemia and Age on Functional Vasodilation
Ischemia impaired functional vasodilation in both young and adult mice with only
10-15% increase in diameter of the ischemic leg, compared to 100-140% for the sham
limb. Ischemia causes cells to release vasoactive products such as NO [65]. The response
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to this hypoxia such as molecule concentration and duration, depends upon degree and
duration of the hypoxic injury [7]. The ischemia surgery induces a significant amount of
inflammation, which was visually assessed through the observation of connective tissue
over the surgical site after 14 days. Even though it is such a long time after an
inflammatory response, the mouse could have aggravated the inflammatory response
through scratching or biting of the surgical area during the 14 days of recovery. Several
mice bit off their tails after 14 days; this could be due to the pain at the surgical site,
however great efforts were taken to mitigate this through an injection of buprenorphrine
after surgery. Increased monocyte recruitment to the area due to the inflammation could
have led to a larger resting diameter through the release of vasodilatory factors.
Due to the significantly different vasodilatory response between the sham and
ischemic arteries, the increase in diameter could also be attributed to improper surgical
technique. The only time the profunda femoris artery was touched during the resection
surgery was when the artery and vein pair was cauterized as proximal to the femoral
artery as possible. One of the problems with using cautery is heat propagation through the
surrounding tissue [66]. When heat propagates through a tissue, it causes cellular
temperature to rise, leading to death of the cell. If the heat propagates too far or gets too
hot, less viable tissue remains. Thus, with increased heat propagation, a smaller section of
artery can be analyzed 14 days later. Also, this heat could have propagated into the artery
and caused a significant amount of endothelial dysfunction, creating a difference in
diameter. Heat ablation causes intimal thickening as well as activation of the coagulation
cascade, which is “dose dependent”; meaning a larger amount of heat application from
the cautery would increase the negative effects [67, 68]. Due to the fact that the heat
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cautery is battery operated, the actual temperature of the cautery tip, and the time spent
cauterizing the artery was variable for each surgery. If the cautery tip was left near the
tissue for too long, the surrounding area would become burnt and charred. This occurred
only a few times, but was the result of improper cautery equipment or technique. Extra
effort was made to make sure that this never happened to the tissue; however the variable
cautery temperatures made this difficult. After a new cautery was acquired, resting
diameters and tissue charring decreased.
Another possible explanation for the increased artery diameter, which may have
reduced the dynamic range and dilation potential of the vessel, is the tissue dissection
technique of the ischemic limb before the intravital microscope and microelectrodes were
placed. If there was a significant inflammatory response to the surgery, there was a
significant amount of connective tissue that needed to be dissected in order to clearly
visualize the artery. Even if it was visible through the light microscope, a layer of
connective tissue on top of the profunda femoris artery could prevent successful focusing
of the intravital microscope. Also, if the tissue around the artery was agitated during
dissection, this could have injured and dilated the profunda femoris artery. Extra care was
taken to ensure that the connective tissue was carefully dissected away from the artery
before measurements were taken.
Several other precautions were taken during the experiment in order to maintain
consistency between subjects. The ischemic and sham legs measurements were alternated
as recommended by a previous researcher in the lab, Matt Yocum [58]. Even with efforts
to improve consistency, there was still a significant difference between the two groups.
This further supports the theory that the surgery affected the artery in some way.
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The result of a high resting diameter was most likely due to the cautery and
surgical/dissection technique. After performing several surgeries and dissections, my
technique and consistency improved. Additionally, with the acquisition of the new
cautery, the issue of large resting diameters disappeared.

Aim 1: Future Recommendations
Several problems were observed with the current imaging protocol. As previously
mentioned, the MicroScan intravital microscope has an immersion lens, leaving very
little space between the microscope tip and underlying tissue. Contact between these two
surfaces may irritate the artery and cause it to dilate. Also, due to the nature of the
surgery that is used and the experimental model, finding a clear picture of the artery is
sometimes difficult (Figure 36). An elevated inflammatory response due to surgical
trauma can cause a buildup of connective tissue and/or increase vascularization. This
causes a reduction in image clarity and sometimes vascular response to stimulus.
Furthermore, with older or larger mice, increased adipose tissue can cause similar
difficulties.
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A

B

Figure 36: Poor Vessel Images. Examples of poor image quality of vessel due to (A)
vascularization due to inflammatory response (B) overlying adipose tissue due to larger
or older mouse

For future researchers interested in assessing the impact of age and ischemia on
vasodilation, several topics must be analyzed further. Further research is needed to
determine why there was a significant difference between resting diameters in the
experimental and sham profunda femoris. By using a superfusion setup, pharmacological
agents can be added to the artery and help further explain the cellular pathways that could
be dysfunctional. First, this experiment should be repeated using the proper cautery to
potentially eliminate that variable. Eventually, pharmacological inhibitors to vasodilation
could be superfused before and after stimulation to block hypothesized pathways.
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AIM 2: DEVELOPMENT OF FUNCTIONAL VASODILATION PROTOCOL FOR
PHARMACOLOGICAL DELIVERY
In the lab, there currently is no way to electrically stimulate the gracilis muscle
while delivering pharmacologic agents to the area. This protocol solves the problem of
not being able to add drugs to the preparation through mineral oil. By adding the drugs to
a superfusion solution, pharmacological agents can be easily added to the preparation.
The goal was to create a consistent protocol with minimal dilation caused by the
superfusion solution. A superfused functional vasodilation protocol would allow for
further research into the impact of ischemia on the cellular pathways controlling
vasodilation. Pharmacological factors could be added to the superfusion solution to
enhance or inhibit factors in the cellular pathways, creating an opportunity to assess
causal relationships. Irrigating the exposed tissue with an isotonic, degassed solution
allows for the delivery of pharmacological agents while preventing desiccation and
minimizing oxygen diffusion.
The results of the protocol showed a significant increase in diameter,
approximately 75%, after the addition of the superfusion solution to the preparation.
Because of the pre-dilation, it creates a higher resting diameter for the artery, reducing its
maximal dilation potential. The intention of the protocol development was to minimize
this increase in response to the superfusion solution and increase the consistency of the
data collection. Consistency is desired due to the variable nature of the surgical model
that is used. Dr. Steven Segal of the University of Missouri, a veteran in superfusion
protocols, was consulted during this protocol development and made some
recommendations on how to improve the superfusion experimental protocol.
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Aim 2: Completed Modifications
One of the first controls put into place was monitoring the pH of the physiological
salt solution, because changes in pH can alter vessel tone and oxygen exchange with
tissues [1]. Another recommendation was bubbling the solution with CO2:N2 gas before
superfusing it over the hindlimb. N2 gas is used because helps deoxygenate the solution.
This is important because oxygen transport from the atmosphere directly to skeletal
muscle will cause the smooth muscle to constrict [2]. The combination of these
modifications produced an interesting result. Right after the PSS was mixed, the pH was
measured and averaged 7.9; after the PSS was bubbled, pH decreased to 7.1. Both of
these values are above and below the desired pH values (7.30 - 7.35), respectively. The
pH was then measured after it had flowed through the circuit and was within desired
values, this was possibly due to the carbon dioxide diffusion out of the solution during
the time it was in the circuit. Efforts were made to pH balance the solution before adding
it to the irrigation circuit; however this did not produced positive results. Further,
application of varying pH levels, demonstrated that a change in pH was not the cause of
the resting vasodilation.
In addition to pH, vascular tone is also affected by temperature. Thus, another
modification was to vary the temperature and flow rate of the solution. Previous
investigators maintained the PSS at 35 ºC with a flow rate of ~2mL·min-1 [47]. Adjusting
the syringe heater the flow rate could both change the temperature due to the gain and
loss of temperature through the circuit, respectively. Great efforts were taken to minimize
this temperature loss by insulating the circuit, but a temperature loss of about 10 ºC from
the beginning to end of the circuit was still observed. Both the temperature and flow rate
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changed throughout the experiment and extra care was taken to maintain both of these
values close to preferred ranges. Dr. Segal recommended that a temperature of 37 ºC
should be used. Unfortunately, a similar loss of vessel tone was seen at both high (40 ºC)
and low (30 ºC) temperatures.
Given that changes in PSS properties did not affect vascular tone, it was also
speculated that the shear stress between the surface of the profunda femoris artery and the
intravital microscope lens caused vasodilation. To test this, the intravital microscope was
removed and the vessel was observed with a stereo light microscope, which has a ~10 cm
working distance and does not directly contact the tissue. Unfortunately, altering the flow
conditions of the PSS over the profunda femoris did not impact the resting vasodilation.
After eliminating temperature and pH, other variables that were analyzed were the
freshness of the solution and the cleanliness of the superfusion circuit equipment. This
recommendation was made because the salts in the solution and superfusion circuit
precipitate in the solution and adsorb in the circuit, causing changes in the concentration
of the different compounds. Due to the potential buildup of salts in the circuit, the dishes
cleaning protocol was changed, implementing a different rinse into the process, and
changing out all of the tubing that was used with new tubing. It was also determined that
a piece of metal in the circuit was corroding from the acid rinse during the cleaning
protocol. The metal was replaced with a plastic piece to prevent this corrosion. Again, no
difference in vessel tone was observed with these changes.
Since precipitated salts were not causing the problem, the final variable to change
was the actual salts used in the solutions. The compounds used were the same; however
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the product numbers were different from those of Dr. Segal’s group. Even after changing
to the same product numbers, similar results were seen with loss of vessel tone 30
minutes after the superfusion solution was applied.

Aim 2: Future Recommended Modifications
Recommended modifications involve gaining more control of the superfusion
circuit. The following variables changed throughout the experiment: gas bubbling rate,
flow rate and temperature. Often times during the experiment, the rate of bubbling in the
solution was variable. To solve this problem the bubbling rate of the superfusion solution
needs to be higher to prevent a decrease in bubbling rate that was seen. The level of
superfusion liquid was kept at 60 mL in the syringe heater, leaving a small volume for the
bubbling solution. Decreasing this volume to 50 mL in the syringe will allow more room
for bubbling at a higher rate without the solution spilling out of the top of the syringe. To
maintain temperature and flow rate, flow rate must be more accurately controlled.
Currently, flow rate is monitored through compressing a tube with a screw clamp. It is
difficult to obtain and maintain using this method.
Flow over the profunda femoris artery must also be consistent. Often, the
intravital microscope prevented flow over the artery if it was depressed too much. The
positive effect was lack of vasodilation of the artery, however if a drug was in the
superfusion solution, it had no effect on the artery. To combat this problem, a different
intravital microscopy method is needed. This could be accomplished by using a
microscope with a larger working distance, such as a compounded reflected light
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microscope; so more space could be put between the microscope and the profunda
femoris artery.
The development of a consistent superfused functional vasodilation protocol is
imperative for future understanding of endothelial dysfunction due to ischemic injury.
The ability to target and inhibit or enhance specific cellular mechanisms during a
functional vasodilation experiment is essential for determining the impact of ischemia on
this process.

AIMS 3 AND 4: IMPACT OF ISCHEMIA ON CELL DEPENDENT DILATION AND
CONSTRICTION
Previous work has demonstrated impaired vasodilation in arterioles, but the effect
of ischemia on feed arteries is unknown. Understanding how ischemia affects feed
arteries is important because feed arteries play a critical role in determining tissue blood
flow. A healthy artery has the ability to vasodilate and vasoconstrict in order to ensure the
homeostasis of oxygen and other nutrients of the downstream tissues. In response to acute
ischemia/hypoxia, vessels dilate to increase the blood flow to the affected area.
Unfortunately, chronic ischemia leads to vasodilatory dysfunction. Ischemic arterioles in
the lower leg have impaired functional vasodilation, which could be explained by
impaired endothelial-dependent dilation [69, 70]. Similar results were found in rat
collateral arteries in vitro [71]. In both studies, exercise restored endothelial function.
Due to this result, it was hypothesized that post-resected mice would present a similar
endothelial dysfunction and dilate less to ACh than SNP.
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Aim 4: Possible Smooth Muscle Dysfunction
Due to the fact that ACh and SNP produced similar results and there was no
significant difference between the two treatments, smooth muscle dysfunction is the best
reason for this result. Since only three pharmaceuticals were used in the experiment,
further research is needed to discover what mechanism is dysfunctioning. One
explanation for why smooth muscle dependent process would be impaired is due to the
pressure in the profunda femoris artery. The surgical removal of the femoral artery,
which feeds the profunda femoris, is assumed to decrease pressure the ischemic side.
Knowing the pressure could help further differentiate the role of cellular dysfunction in
smooth muscle cells versus altered vasodilation due to changes in hemodynamics. There
could be a biochemical difference in the smooth muscle causing dysfunction as well.
To better understand the resulting pathology of the resection surgery, further
research must be done to fully rule out endothelial dysfunction. In addition to using
endothelial-dependent vasodilators, the impact of ischemia on the endothelium can be
assessed by damaging or removing the endothelium. The endothelium can be damaged by
perfusing an air bubble through the vessel or by using an intravascular dye that heatinjures the endothelium following excitation [47].
Vasoconstriction was also analyzed to fully understand the dynamic range of the
artery. Previous groups have shown an increased vasoconstrictive response by ischemic
limbs [51] while others have shown a reduction in sympathetic tone with chronic
ischemia [41]. In this study, both groups responded similarly to neuroepinephrine. This
discrepancy could have contributed to the difficulty in measuring the vessel when it was
vasoconstricted, as the differences in such a small diameter were difficult to differentiate
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due to the microscope resolution. Also, due to the fact that the previous demonstration of
enhanced constriction was performed with human tissue, there are several comorbidities
involved in the patient when compared to the mouse that could explain this difference,
such as hypertension.

Differences between Superfusion and Functional Vasodilation
There are some observed differences between the functional vasodilation and
superfusion results. The measured resting values of the ischemic limbs are different. For
both the young and adult mice in the first aim, they are around 100 µm. In the fourth aim,
the resting diameter is around 80 µm.
First, the differences in ischemic resting diameter will be addressed. In previous
work from Matt Yocum, possible causes of an increased diameter was a decreased time
between dissection and measurement, and contact between the MicroScan tip and the
profunda femoris artery [58]. These recommendations were understood before both aims.
When a higher resting diameter was noticed, more time was added to the timer (more
than 30 minutes) and great care was taken to move the MicroScan as high as possible to
prevent contact between it and the underlying tissue.
One possible hypothesis to this observed difference in resting values could be the
difference in surgical equipment and technique used between the two aims. The cautery
used in the first aim was old and inconsistent and was replaced with brand new cautery
after Aim 1 was completed. This created a more consistent heat profile that burned
through the artery faster, allowing for more visible artery length 14 days later. There was
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also a difference in technique that was used during dissection before the superfusion
experiment in aim 4. Microdissection scissors were used to carefully cut away the
connective tissue above the profunda femoris artery, as opposed to careful blunt
dissection that was previously used. This could have caused less stretching of the artery,
allowing for less distress to the artery and surrounding tissue.
In summary, ischemia impairs vascular reactivity however it remains unclear if it
is endothelial dysfunction or smooth muscle dysfunction. The proposed data implies
smooth muscle dysfunction; however more research needs to be completed to fully rule
out endothelial dysfunction.

FINAL CONCLUSIONS
This study has shown that ischemia and age significantly affect vascular function.
Determining the cause of this dysfunction requires additional studies and protocol
improvements. This leads to further possibilities of research with this model. First a few
key problems need to be addressed.
The resection model proves to be difficult due to the current experimental setup.
This model could become a more viable option if the surgical protocol did not involve
cautery, a method that as stated previously is hard to control with current equipment.
Also, using a microscope that allows for a larger focal distance that restricts tissue
contact will help control the model to allow for more consistent results. Digital calipers
will also provide a more controlled and consistent method to measure arterial diameters.
Once these problems are addressed future experimental methods can be attempted.
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As stated in the introduction, mice have a large number of transgenic options to
allow experiments that test causal relationships. Surgical methods also provide
opportunities to look at the possibility of endothelial dysfunction. Superfusion protocols
with different drugs such as inhibitors can help address specific cellular pathway
dysfunctions. Also, with improvements made in superfusion, the effects of age using
cell-specific vasoactive agents can be addressed. Exercise is also a possible treatment to
be attempted, as previous research has showed improvement in endothelial function [41,
70, 71] following exercise. It is still unclear what specifically impairs vascular function in
ischemic conditions; it is the goal of this research to solve those questions. There has
been a history of efficacy of therapies in animal models and disappointing results seen in
randomized patient trials, perhaps the current way this model is used is the answer to this
problem.
To better understand the current model and its dysfunction, age must be addressed
with the superfusion protocol to determine if endothelial dysfunction exists in adult mice.
Also, old mice, that could present more dysfunction than young mice, should be
examined. Finally, different pharmaceuticals such as inhibitors need to be used in the
superfusion setup to better differentiate between endothelial dysfunction and smooth
muscle dysfunction.
With the knowledge gained from these results, it is shown that ischemia and age
significantly impairs vasodilation in a feed artery. By improving vasodilation in patients
with ischemia, blood flow could be partially restored. More specifically, therapies
targeting smooth muscle could prove more effective.
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APPENDIX A
RESECTION PROTOCOL

Figure 37: Resection Protocol

85

APPENDIX B
DUAL FUNCTIONAL VASODILATION PROTOCOL

Figure 38: Functional Vasodilation Protocol (Page 1)
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Figure 39: Functional Vasodilation Protocol (Page 2)
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APPENDIX C
SUPERFUSION PROTOCOL

Figure 40: Superfusion Protocol (Page 1)
88

Figure 41: Superfusion Protocol (Page 2)
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APPENDIX D
SUPERFUSED FUNCTIONAL VASODILATION PROTOCOL

Figure 42: Superfused Functional Vasodilation Protocol (Page 1)
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Figure 43: Superfused Functional Vasodilation Protocol (Page 2)
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APPENDIX E
SDF IMAGING ANALYSIS USING AVA SOFTWARE
In order to produce accurate measurements, the MicroScan was first calibrated
according to the manufacturers specifications. For the data collection portion, the
MicroScan was placed on a horizontal plane. This was usually accomplished through
secure placement in the boom stand. It was also important for the MicroScan to not be in
contact with the profunda femoris, but to be as far above it as possible while keeping the
vessel in focus.
In order to record a video, AVA 3.0 was first opened which led to a main menu
screen (Figure 44). After selecting the “data” button, the specific folder where the videos
were saved was chosen. The “capture” button was then selected and specific information
regarding the experiment was entered (mouse tag, sham or exp, etc.). Videos were taken
for 10 seconds by pressing the “start capture” button. These videos were automatically
saved in the folder that was determined earlier in the process.
For data analysis, selecting the “analysis” button opened a video file (Figure 45).
Once the specific video file was chosen, sliding the white bars at the bottom of the screen
chose the number of frames. Then, the “stabilize video” button was chosen and the result
was a video file that stabilized and accounted for the breathing of the mouse. Then, the
outline of the profunda femoris artery was carefully traced and the average diameter was
recorded. This process of analysis was repeated for each video file and was performed the
same way each time.
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Figure 44: AVA
(A) Front screen where options to create folders [Settings], create videos for analysis
[Capture] and analyze videos to create data points [Analysis]. (B) Once selecting
“Capture” the menu allows for creation of videos with [Start capture]
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Figure 45: Image Analysis
(1) Stabilize image before analysis (2) Draw outline of artery (3) Example of artery
outline (4) Delete outline of drawing if not accurate on vessel wall (5) Average diameter
measurement
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